ClinicalTrials.gg
RecruitingNCT07602036pUMPreg2Updated Nov 10, 2026

Type 2 Diabetes and Pregnancy a Single-arm Interventional Study

An interventional study of Automated insulin delivery system - Medtronic 780G in Pregnancy and Type 2 Diabetes, sponsored by Poznan University of Medical Sciences. Recruiting at 1 site in Poland. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Poznan University of Medical Sciences · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 10, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 351 studies in Diabetes Mellitus, Type 2 with a site in Poland — 27 open to participants now, 38 under way, 22 of them phase 3. Diabetes Mellitus, Type 2 · Poland.

Planned enrollment
328th of 333
20 · median 500
Started
2026
with 22 others
No phase
15 of 351
3 open now
Primary completion
2028-10
later than 33 of 37 live
Registered
335th of 351
by date

Among the 351 studies in Diabetes Mellitus, Type 2 with a site in Poland, this one is the 328th largest by planned enrollment of the 333 interventional ones that give a count, is one of 23 that started in 2026, is one of 15 with no phase, reaches primary completion later than 33 of the 37 other live ones, and was the 335th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

27 of the 351 studies in Diabetes Mellitus, Type 2 with a site in Poland are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 351 studies in Diabetes Mellitus, Type 2 with a site in Poland, or all of them as a file.
02

Study summary

This single-arm interventional study evaluates the MiniMed 780G insulin pump and continuous glucose monitoring (CGM) system in pregnant women with type 2 diabetes enrolled at ≤ 16 weeks gestation. From recruitment to delivery, participants attend regular clinical visits for active insulin adjustments. The primary objective is to measure the percentage of time spent in the target pregnancy glucose range (63-140 mg/dL). Secondary outcomes track mean glucose, HbA1c, and overall maternal and neonatal health to ensure safety and efficacy.

Read the detailed description

This study will evaluate the use of the MiniMed 780G insulin pump system in pregnant women with type 2 diabetes. The aim is to assess whether this treatment can help participants achieve good glucose control during pregnancy and support favorable maternal and neonatal outcomes.

This is a single-arm interventional study. All participants will use the same insulin pump and continuous glucose monitoring system from recruitment until delivery. The study will include pregnant women with type 2 diabetes who enter the study at 16 weeks of pregnancy or less.

Participants will attend regular follow-up visits during pregnancy. Researchers will review glucose data, adjust insulin treatment, measure HbA1c, and assess pregnancy and neonatal outcomes.

The main outcome is the percentage of time spent in the pregnancy target glucose range of 63 to 140 mg/dL from recruitment until delivery. The study will also assess mean glucose levels, maternal outcomes, and neonatal outcomes.

03

Conditions studied

  • Pregnancy
  • Type 2 Diabetes

Keywords

  • type 2 diabetes
  • pregnancy
  • insulin pump
  • Automated insulin delivery system
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women with diagnosed pregestational type 2 diabetes or >6.5% in the 1st trimester (ADA, PTD)
  2. Age 18-45 years
  3. Gestational age of 16 weeks +0 days or less at baseline
  4. Singleton pregnancy
  5. HbA1c at baseline 5.0-10%
  6. A viable pregnancy at the recruitment
  7. Willingness to continue the treatment until delivery in the clinic

Exclusion criteria

Exclusion Criteria:

  1. Other types of diabetes including T1D and Monogenic diabetes
  2. Major fetal congenital defects
  3. Severe nephropathy, psychiatric illness or other serious medical disorder that in the judgment of the investigator could affect completion of the trial
  4. Pump therapy before pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Type 2 diabetes

    Pregnant patients with type 2 diabetes treated with automated insulin delivery system

    Device: Automated insulin delivery system - Medtronic 780G

Interventions

  • DeviceAutomated insulin delivery system - Medtronic 780G

    Use of automated insulin delivery system in pregnant patients with type 2 diabetes

06

What researchers measure

Primary outcomes

  1. Time in range

    Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)

    Time frame: From enrollment to the delivery

  2. Mean sensor glycemia

    Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)

    Time frame: From enrollment to the delivery

Secondary outcomes

  1. Time in range

    Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)

    Time frame: Week 18

  2. Time in range

    Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)

    Time frame: Week 22

  3. Time in range

    Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)

    Time frame: Week 26

  4. Time in range

    Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)

    Time frame: Week 30

  5. Time in range

    Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)

    Time frame: Week 34

  6. Time in range

    Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)

    Time frame: Week 37

  7. Time in tight range

    Percentage of time spent in target glucose values - 63-120 mg/dL (3.5-6.7 mmol/L)

    Time frame: Week 18

  8. Time in tight range

    Percentage of time spent in target glucose values - 63-120 mg/dL (3.5-6.7 mmol/L)

    Time frame: Week 22

  9. Time in tight range

    Percentage of time spent in target glucose values - 63-120 mg/dL (3.5-6.7 mmol/L)

    Time frame: Week 26

  10. Time in tight range

    Percentage of time spent in target glucose values - 63-120 mg/dL (3.5-6.7 mmol/L)

    Time frame: Week 30

  11. Time in tight range

    Percentage of time spent in target glucose values - 63-120 mg/dL (3.5-6.7 mmol/L)

    Time frame: Week 34

  12. Time in tight range

    Percentage of time spent in target glucose values - 63-120 mg/dL (3.5-6.7 mmol/L)

    Time frame: Week 37

  13. Change in the time in range values

    Change in percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)

    Time frame: From the recruitment to delivery

  14. Time above range

    Percentage of time spent above target glucose values - \>140 mg/dL (\>7.8 mmol/L)

    Time frame: Week 18

  15. Time above range

    Percentage of time spent above target glucose values - \>140 mg/dL (\>7.8 mmol/L)

    Time frame: Week 22

  16. Time above range

    Percentage of time spent above target glucose values - \>140 mg/dL (\>7.8 mmol/L)

    Time frame: Week 26

  17. Time above range

    Percentage of time spent above target glucose values - \>140 mg/dL (\>7.8 mmol/L)

    Time frame: Week 30

  18. Time above range

    Percentage of time spent above target glucose values - \>140 mg/dL (\>7.8 mmol/L)

    Time frame: Week 34

  19. Time above range

    Percentage of time spent above target glucose values - \>140 mg/dL (\>7.8 mmol/L)

    Time frame: Week 37

  20. Time above tight range

    Percentage of time spent above target glucose values - \>120 mg/dL (\>6.7 mmol/L)

    Time frame: Week 18

  21. Time above tight range

    Percentage of time spent above target glucose values - \>120 mg/dL (\>6.7 mmol/L)

    Time frame: Week 22

  22. Time above tight range

    Percentage of time spent above target glucose values - \>120 mg/dL (\>6.7 mmol/L)

    Time frame: Week 26

  23. Time above tight range

    Percentage of time spent above target glucose values - \>120 mg/dL (\>6.7 mmol/L)

    Time frame: Week 30

  24. Time above tight range

    Percentage of time spent above target glucose values - \>120 mg/dL (\>6.7 mmol/L)

    Time frame: Week 34

  25. Time above tight range

    Percentage of time spent above target glucose values - \>120 mg/dL (\>6.7 mmol/L)

    Time frame: Week 37

  26. Time below range

    Percentage of time spent below target glucose values - \<63 mg/dL (\<3.5 mmol/L)

    Time frame: Week 18

  27. Time below range

    Percentage of time spent below target glucose values - \<63 mg/dL (\<3.5 mmol/L)

    Time frame: Week 22

  28. Time below range

    Percentage of time spent below target glucose values - \<63 mg/dL (\<3.5 mmol/L)

    Time frame: Week 26

  29. Time below range

    Percentage of time spent below target glucose values - \<63 mg/dL (\<3.5 mmol/L)

    Time frame: Week 30

  30. Time below range

    Percentage of time spent below target glucose values - \<63 mg/dL (\<3.5 mmol/L)

    Time frame: Week 34

  31. Time below range

    Percentage of time spent below target glucose values - \<63 mg/dL (\<3.5 mmol/L)

    Time frame: Week 37

  32. Mean sensor glycemia

    Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)

    Time frame: Week 18

  33. Mean sensor glycemia

    Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)

    Time frame: Week 22

  34. Mean sensor glycemia

    Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)

    Time frame: Week 26

  35. Mean sensor glycemia

    Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)

    Time frame: Week 30

  36. Mean sensor glycemia

    Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)

    Time frame: Week 34

  37. Mean sensor glycemia

    Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)

    Time frame: Week 37

  38. Coefficient of variation (%CV)

    Metric of glycemic variability measured by the sensor (%)

    Time frame: Week 18

  39. Coefficient of variation (%CV)

    Metric of glycemic variability measured by the sensor (%)

    Time frame: Week 22

  40. Coefficient of variation (%CV)

    Metric of glycemic variability measured by the sensor (%)

    Time frame: Week 26

  41. Coefficient of variation (%CV)

    Metric of glycemic variability measured by the sensor (%)

    Time frame: Week 30

  42. Coefficient of variation (%CV)

    Metric of glycemic variability measured by the sensor (%)

    Time frame: Week 34

  43. Coefficient of variation (%CV)

    Metric of glycemic variability measured by the sensor (%)

    Time frame: Week 37

  44. Standard deviation (SD)

    Metric of glycemic variability measured by the sensor (mg/dL and mmol/L)

    Time frame: Week 18

  45. Standard deviation (SD)

    Metric of glycemic variability measured by the sensor (mg/dL and mmol/L)

    Time frame: Week 22

  46. Standard deviation (SD)

    Metric of glycemic variability measured by the sensor (mg/dL and mmol/L)

    Time frame: Week 26

  47. Standard deviation (SD)

    Metric of glycemic variability measured by the sensor (mg/dL and mmol/L)

    Time frame: Week 30

  48. Standard deviation (SD)

    Metric of glycemic variability measured by the sensor (mg/dL and mmol/L)

    Time frame: Week 34

  49. Standard deviation (SD)

    Metric of glycemic variability measured by the sensor (mg/dL and mmol/L)

    Time frame: Week 37

  50. HbA1C

    Blood glycated hemoglobin measurement (% and mmol/mol)

    Time frame: Week 18

  51. HbA1C

    Blood glycated hemoglobin measurement (% and mmol/mol)

    Time frame: Week 22

  52. HbA1C

    Blood glycated hemoglobin measurement (% and mmol/mol)

    Time frame: Week 26

  53. HbA1C

    Blood glycated hemoglobin measurement (% and mmol/mol)

    Time frame: Week 30

  54. HbA1C

    Blood glycated hemoglobin measurement (% and mmol/mol)

    Time frame: Week 34

  55. HbA1C

    Blood glycated hemoglobin measurement (% and mmol/mol)

    Time frame: Week 37

  56. Severe hypoglycemia episodes

    Number of episodes of self-reported severe hypoglycemia.

    Time frame: From recruitment until delivery.

  57. Gestational weight gain

    Maternal gestational weight gain (kg)

    Time frame: From recruitment until delivery

  58. Gestational weight gain from pre-pregnancy

    Self-reported maternal gestational weight gain (kg)

    Time frame: From pre-pregnancy until delivery

  59. Pregnancy hypertensive disorders

    Preeclampsia, Eclampsia, Gestational hypertension

    Time frame: From recruitment until delivery

  60. The mode of delivery

    Vaginal, c-section, spontaneous, induction of labor

    Time frame: At delivery

  61. Birth trauma

    IADPSG criteria

    Time frame: At delivery

  62. Gestational birth weight

    Neonatal birth weight in grams

    Time frame: At delivery

  63. Macrosomia

    Gestational birth weight \>4200g

    Time frame: At delivery

  64. Large-for-gestational-age (LGA)

    Neonatal birth weight \>90th percentile

    Time frame: At delivery

  65. Small-for-gestational-age (SGA)

    Neonatal birth weight \<10th percentile

    Time frame: At delivery

  66. Placental weight

    Measured in grams

    Time frame: At delivery

  67. Gestational age

    Timing of delivery

    Time frame: At delivery

  68. Preterm birth

    \<37 weeks

    Time frame: At delivery

  69. Number of neonates with respiratory distress syndrome

    Defined as the number of neonates diagnosed with respiratory distress syndrome during the postnatal hospital stay, based on clinical signs of respiratory distress and the need for respiratory support, with or without radiological confirmation, according to local neonatal clinical practice.

    Time frame: From delivery until hospital discharge, assessed up to 20 weeks postpartum

  70. Number of neonates with jaundice requiring phototherapy

    Defined as the number of neonates diagnosed with neonatal jaundice requiring phototherapy during the postnatal hospital stay. Phototherapy requirement will be determined according to local neonatal clinical practice based on serum or transcutaneous bilirubin assessment.

    Time frame: From delivery until hospital discharge, assessed up to 20 weeks postpartum

  71. Number of neonates with neonatal hypoglycemia

    Neonatal hypoglycemia - glucose concentrations in neonatal blood \<40 mg/dL (2.2 mmol/L) in a single laboratory measurement at least 3 hours after birth, in the first 24 hours of life

    Time frame: Assessed from delivery until 24 hours postpartum

  72. Stillbirth

    Pregnancy loss after 22 weeks

    Time frame: From week 22

  73. Neonatal length of hospital stay

    Duration of neonatal hospitalization, measured in days

    Time frame: From date of delivery until the date of hospital discharge, assessed up to 20 weeks

  74. Length of stay in the neonatal intensive care unit (NICU)

    Duration of NICU stay, measured in days

    Time frame: From date of NICU admission until the date of NICU discharge, assessed up to 20 weeks

  75. Neonatal acidosis

    Umbilical pH \<7.15

    Time frame: At delivery

  76. Apgar score

    Apgar score \<8

    Time frame: At delivery

07

Study locations

1 of 1 sites recruiting
  • Heliodor Swiecicki Clinical Gynecology and Obstetrics Hospital of Poznan University of Medical Sciences
    Poznan, Wielkopolska 60-535, Poland
    Recruiting
    • Ewa Wender-Ozegowska, Prof. MD PhD · Contactewozegow@ump.edu.pl · +48 (61) 841-93-02
    • Ewa Wender-Ozegowska, Prof. MD PhD · Principal investigator
08

References and documents

Publications

  • Gladych-Macioszek A, Mantaj U, Tobola-Wrobel K, Radzicka-Mularczyk S, Sibiak R, Adamczak L, Desoye G, Wender-Ozegowska E. Early gestational diabetes mellitus and type 2 diabetes: do they differ in perinatal outcome- a retrospective analysis. BMC Pregnancy Childbirth. 2026 Mar 11;26(1):423. doi: 10.1186/s12884-026-08927-3. PubMed 41807957 ↗
  • Sibiak R, Iciek R, Gastolek K, Chudzynska E, Meek C, Wender-Ozegowska E. Ten-year national trends in the prevalence and outcomes of gestational diabetes mellitus in Poland: a population-based study. Pol Arch Intern Med. 2026 Feb 26;136(2):17202. doi: 10.20452/pamw.17202. Epub 2026 Jan 19. PubMed 41562177 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Oct 2028, 29 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 29 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
May 22, 2026
StartActual
May 8, 2026
Primary completionEst.
Oct 2028
CompletionEst.
Feb 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
Heliodor Swiecicki Clinical Gynecology and Obstetrics Hospital of Poznan University of Medical Sciences is now Recruiting
Nov 10, 2026
Start date
May 1, 2026→May 8, 2026 (actual)
Nov 10, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionSmall-for-gestational-age (SGA): how it is measured was reworded
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    Heliodor Swiecicki Clinical Gynecology and Obstetrics Hospital of Poznan University of Medical Sciences is now Recruiting
    Start date May 1, 2026→May 8, 2026 (now actual)
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionSmall-for-gestational-age (SGA): how it is measured was reworded
    + 3 other changes: verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07602036
Collaborators
Medtronic
Responsible party
Sponsor
First posted
May 22, 2026
Start date
May 8, 2026
Primary completion
Oct 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Ewa Wender-Ozegowska, Prof. MD PhD
Contact
ewozegow@ump.edu.pl
+48 (61) 841-93-02
Ewa Wender-Ozegowska, Prof. MD PhD
principal investigator · Poznan University of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion